trending Market Intelligence /marketintelligence/en/news-insights/trending/BtSgqCA5S02C4AyoCH56ag2 content esgSubNav
In This List

Salarius Pharma gets US FDA fast-track tag for drug to treat rare bone cancer

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector

Blog

Insight Weekly: Energy reforms after midterms; Crisis ends 'age of gas'; bank deposits fall


Salarius Pharma gets US FDA fast-track tag for drug to treat rare bone cancer

Salarius Pharmaceuticals Inc.'s drug to treat a rare bone cancer called seclidemstat has received the U.S. Food and Drug Administration's fast-track designation.

Fast-track designation means Houston-based Salarius will communicate more frequently with the FDA and receive an expedited development and review process for seclidemstat.

The drug is intended to treat Ewing sarcoma, most common in children and young adults, that has returned or is resistant to standard-of-care therapy, according to Salarius' Dec. 16 press release. Seclidemstat, which blocks the overexpressed LSD1 enzyme, previously received orphan-drug and rare pediatric disease designations from the FDA.

No targeted therapies are approved to treat Ewing sarcoma, Salarius said.

Seclidemstat is now in a phase 1/2 clinical trial for the disease and is also being tested in advanced solid tumors such as prostate, breast and ovarian cancers.